Clinical Trial Results:
            A randomized, double-blind, controlled phase III study of Stimuvax® (L-BLP25 or BLP25 liposome vaccine) in combination with hormonal treatment versus hormonal treatment alone for first-line therapy of post-menopausal women with estrogen receptor (ER)-positive and/or progesterone receptor (PgR)-positive, inoperable locally
advanced, recurrent, or metastatic breast cancer
STRIDE - STimulating immune Response In aDvanced brEast cancer
    
|     Summary | |
|     EudraCT number | 2008-005544-17 | 
|     Trial protocol | CZ SE BE DE HU NL IE AT PT FR IT SK GR ES | 
|     Global completion date | 
                                    10 Sep 2010
                             | 
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | 
                                        No
                                 | 
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    29 Jun 2016
                             | 
|     First version publication date | 
                                    29 Jun 2016
                             | 
|     Other versions | |
|     Summary report(s) | 2008-005544-17_CT.gov results | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
